while in the rapidly evolving subject of oncology study, accurate and effective mutation screening is crucial for developing focused therapies. The KRAS providers Platform plays a pivotal job During this landscape by featuring in depth alternatives for KRAS mutation profiling and Assessment. KRAS mutations, found in roughly 95% of RAS-related oncog